Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?

ABSTRACT: Multiple myeloma (MM) is characterized by recurrent relapses. Consequently, patients receive multiple therapy lines, including alkylating agents and immune modulators, which have been associated with secondary malignancies such as myelodysplastic syndrome (MDS). Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T cell (CART) therapy is efficacious in patients with relapsed/refractory (R/R) MM. However, the long-term complications, particularly MDS, are not well understood. Whether CART therapy causes or promotes MDS has not been thoroughly investigated. In this study, we explored the causal relationship between MDS and CART therapy. We retrospectively examined the prevalence of MDS-related morphological and mutational changes before and after administration of CART therapy in

SUBMITTER: Vainstein V 

PROVIDER: S-EPMC10341314 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature